Vaccinex, Inc.

University of Rochester

Ernest S Smith

Maurice Zauderer

Mark Paris

Terrence Lee Fisher

Elizabeth E Evans

Renee A Kirk

Angelica A Cornelison

Maria G M Scrivens

William J Bowers

Leslie A Croy

Alan Jonason

Ekaterina Klimatcheva

Tracy Pandina

Leslie A Balch

Angelica Moksa

Shuying Shi

Masaru Yoshida

Terrence L Fisher, Sr

Pamela M Holland

Andrew Lake

Wei Wang

Koji Yamamoto

John R Basile

Austin Dulak

Caroline Harvey

Maria Scrivens

Christopher Converse Wells

Sonia G Das

Loretta Mueller

Angelika Moksa

Deepak M Sahasrabudhe

Mark J Paris

Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.

Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis

Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Anti-CD100 antibodies and methods for using the same

Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.

Human anti-semaphorin 4D antibody

Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.

Anti-CXCL13 antibodies and methods of using the same

This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.

Integral membrane protein display on poxvirus extracellular enveloped virions

The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

Anti-CCR8 antibodies and uses thereof

This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.

Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.

Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability

Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases

This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.

Polynucleotides encoding anti-CXCL13 antibodies

Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit

Growing community of inventors

Ontario, NY, United States of America

Ernest S Smith